NCT01653561View on ClinicalTrials.gov

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Breast Neoplasms
Interventions
DRUG

Apatinib

The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.

Trial Locations (2)

200032

Fudan University Cancer Hospital, Shanghai

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER

NCT01653561 - A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter